The postcoital test in the development of new vaginal contraceptives†.

diaphragm ferrous gluconate (iron) monthly non-coital nonhormonal postcoital test sperm motility and transport vaginal contraception vaginal ring or device

Journal

Biology of reproduction
ISSN: 1529-7268
Titre abrégé: Biol Reprod
Pays: United States
ID NLM: 0207224

Informations de publication

Date de publication:
04 08 2020
Historique:
received: 04 02 2020
revised: 21 05 2020
accepted: 12 06 2020
pubmed: 14 7 2020
medline: 25 9 2021
entrez: 14 7 2020
Statut: ppublish

Résumé

Postcoital tests (PCTs) have been used for over a century in the clinical evaluation of infertile couples, and for nearly 70 years in the evaluation of new vaginal contraceptive products. PCTs have been largely replaced by more modern methods in the study of infertility, but they remain the most useful way to obtain preliminary data on the effectiveness of vaginal contraceptive products. The World Health Organization has described important aspects of the procedure. It involves collection of cervical mucus at a certain time point after intercourse and the counting and characterization of sperm found in the mucus. A wide range of progressively motile sperm (PMS) has been associated with pregnancy rates in infertility studies. Eligibility for contraceptive trials includes the requirement that couples achieve a certain threshold number of PMS per high power field at midcycle in a baseline cycle without the test product. The primary endpoint, or definition of a satisfactory result in test cycles, is predefined. A literature review identified 10 PCT studies of vaginal contraceptives involving nine test products. Phase II trials of vaginal contraceptives have not been deemed feasible in the development of any vaginal contraceptive to date. A PCT study of a test product can be predictive of contraceptive efficacy, although ultimate contraceptive effectiveness is influenced by the ease of use of the product, along with patient compliance. PCT results similar to results seen with products that later showed satisfactory performance in efficacy trials is the best indicator of likely success of a test product.

Identifiants

pubmed: 32657328
pii: 5858030
doi: 10.1093/biolre/ioaa099
pmc: PMC7401356
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

437-444

Subventions

Organisme : NICHD NIH HHS
ID : R44 HD095724
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of Society for the Study of Reproduction. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

Contraception. 1996 Jun;53(6):329-35
pubmed: 8773419
Hum Fertil (Camb). 2002 Feb;5(1 Suppl):S3-8
pubmed: 11897908
Obstet Gynecol. 2015 Apr;125(4):895-903
pubmed: 25751199
Fertil Steril. 1994 Jan;61(1):44-52
pubmed: 8293843
Contraception. 1997 Aug;56(2):97-102
pubmed: 9315418
Acta Obstet Gynecol Scand. 2014 Sep;93(9):913-20
pubmed: 24946691
Fertil Steril. 1977 Nov;28(11):1133-45
pubmed: 923832
Int J Fertil Menopausal Stud. 1996 Jul-Aug;41(4):405-11
pubmed: 8894798
Am J Obstet Gynecol. 1990 Mar;162(3):615-20
pubmed: 2180299
Hum Reprod. 1997 Jul;12(7):1582-8
pubmed: 9262301
J Reprod Med. 2009 Nov-Dec;54(11-12):685-90
pubmed: 20120902
Obstet Gynecol. 1995 Mar;85(3):396-400
pubmed: 7862379
Am J Obstet Gynecol. 1975 Feb 1;121(3):387-93
pubmed: 1115153
Fertil Steril. 1972 Jan;23(1):29-32
pubmed: 5008947
J Clin Endocrinol Metab. 2001 Feb;86(2):594-600
pubmed: 11158014
PLoS One. 2009;4(1):e4294
pubmed: 19173002
Hum Reprod. 1987 Nov;2(8):665-71
pubmed: 3437045
Br J Obstet Gynaecol. 1995 Aug;102(8):621-4
pubmed: 7654639
Fertil Steril. 1976 Feb;27(2):117-29
pubmed: 1248657
Andrologia. 1990 May-Jun;22(3):269-73
pubmed: 2240622
Contraception. 1996 Jun;53(6):353-6
pubmed: 8773422
Contraception. 1999 Aug;60(2):71-80
pubmed: 10592853
Contraception. 2008 Sep;78(3):237-44
pubmed: 18692615
Contraception. 1995 Sep;52(3):167-73
pubmed: 7587188
Obstet Gynecol. 2010 Dec;116(6):1265-73
pubmed: 21099590
Fertil Steril. 1984 May;41(5):703-8
pubmed: 6714448
BMJ. 1998 Aug 22;317(7157):502-5
pubmed: 9712594
Contraception. 2004 Sep;70(3):227-31
pubmed: 15325892
J Am Med Assoc. 1953 Jul 11;152(11):1042-3
pubmed: 12255243
Mol Cell Proteomics. 2007 Apr;6(4):708-16
pubmed: 17220477
Contraception. 1997 Aug;56(2):89-96
pubmed: 9315417
Hum Reprod. 2000 Sep;15(9):1953-7
pubmed: 10966993
Fertil Steril. 1974 Feb;25(2):145-8
pubmed: 4811084
Contraception. 2017 Aug;96(2):124-130
pubmed: 28606382
Sci Rep. 2019 Nov 18;9(1):16993
pubmed: 31740753
Am J Obstet Gynecol. 1994 Jul;171(1):65-70
pubmed: 8030736
Contraception. 1997 Aug;56(2):111-5
pubmed: 9315420
Br J Obstet Gynaecol. 1982 Apr;89(4):299-305
pubmed: 6896155
Contraception. 2004 Dec;70(6):492-7
pubmed: 15541412
Br Med J. 1868 Nov 7;2(410):492-4
pubmed: 20745321

Auteurs

Christine K Mauck (CK)

Daré Bioscience Inc., San Diego, CA, USA.

Kathleen L Vincent (KL)

Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH